Fewer than a tenth of people that would benefit from GLP-1 drugs like Wegovy can access them, states the global health agency as it releases its inaugural advice on the drugs.
With over a billion individuals worldwide currently obese, it is urging broader and more equitable availability to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The latest guidance affirms that obesity is a lifelong illness that can be treated with holistic and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are major obstacles to widespread access to the jabs that can help people shift considerable body mass, notes the organization.
GLP-1 Therapy Scarcity
Even in the current most optimistic outlook, the manufacturing of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, according to the health organization.
The guideline encourages countries and companies to increase access, through measures including voluntary licensing.
Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs replicate a natural hormone to reduce digestion speed, curb appetite and enhance satiety so people eat less.
People usually begin shedding pounds in the initial weeks of commencing the regular doses.
Studies suggests users may regain a significant portion within a year of stopping the medication, as their typical hunger resume.
Being above a healthy weight elevates your likelihood for contracting medical conditions, like type 2 diabetes, heart disease, stroke, and some malignancies.
Excess weight concerns people in every country and was associated with over three and a half million fatalities worldwide in 2024, as per the WHO.
